medRxiv Oncology· Thompson, A. M., Meisner, A., Albain, K. S., Tang, C., Biswas, D., Park, J., Zeng, K., Cappadona, J., Liu, C., McClean, A., Berrevoets, J., Bao, L., Machura, B., Witowski, J., Geras, K. J., Speers, C. W., Hayes, D. F., Kalinsky, K., Sharma, P., Rae, J. M., Godwin, A. K. ·· 22 小时前评分51
Ataraxis Breast CTX 在 SWOG-8814 试验中的盲态外部验证：评估淋巴结阳性 HR+ 乳腺癌预后与化疗获益
AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial
导读
Ataraxis Breast CTX 在 SWOG-8814 盲态外部验证中显示预后价值，并为化疗获益分层提供提示性交互证据。
来源：medRxiv Oncology · medrxiv.org